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ABSTRACT
Background: Plasma total homocysteine (tHcy) is a cardiovas-
cular disease risk factor and is related to several components of
the established cardiovascular disease risk profile. Cysteine is
structurally and metabolically related to homocysteine, but data
on its association with cardiovascular disease and cardiovascular
disease risk factors are sparse.
Objective: Our objective was to search for the determinants
of plasma total cysteine (tCys) and compare them with those
of tHcy.
Design: In this cross-sectional study, we studied 7591 healthy
men and 8585 healthy women aged 40–67 y with no history of
hypertension, diabetes mellitus, coronary heart disease, or cere-
brovascular disease.
Results: In the group aged 40–42 y, tCys was significantly higher
in men (x–: 273 mmol/L; 2.5–97.5 percentile: 219–338 mmol/L)
than in women (253 mmol/L; 202–317 mmol/L) (P < 0.001). In the
group aged 65–67 y, there was no significant sex difference in tCys:
men (296 mmol/L; 233–362 mmol/L) and women (296 mmol/L;
234–361 mmol/L). As with tHcy, tCys was positively associated
with age, total cholesterol concentration, diastolic blood pressure,
and coffee consumption. Body mass index was a strong determi-
nant of tCys but was not related to tHcy. Several factors known to
influence tHcy, including smoking status, folate and vitamin
intake, heart rate, and physical activity, were not associated or
were only weakly associated with tCys.
Conclusion: Plasma tCys is strongly related to several factors
that constitute the cardiovascular disease risk profile. This
should be an incentive to determine the role of tCys in cardio-
vascular disease. Am J Clin Nutr 1999;70:1016–24.
KEY WORDS Plasma total cysteine, homocysteine, body
mass index, total cholesterol concentration, coffee consumption,
blood pressure, humans, cardiovascular disease risk factors,
lifestyle, Hordaland Homocysteine Study, Norway
INTRODUCTION
About 100 epidemiologic and clinical studies that included
> 10 000 case subjects and an equal number of control subjects
have shown that elevated plasma total homocysteine (tHcy) is an
independent risk factor for occlusive disease in the coronary,
cerebrovascular, and peripheral vessels and for arterial and
venous thrombosis (1–5).
Homocysteine is formed from the essential amino acid methio-
nine as a product of numerous S-adenosylmethionine–dependent
transmethylation reactions (6). Homocysteine may be remethyl-
ated to methionine. This reaction is in most tissues catalyzed by
the ubiquitous enzyme 5-methyltetrahydrofalate–homocysteine
S-methyltransferase (methionine synthase), which requires vita-
min B-12 as a cofactor and methyltetrahydrofolate as a cosub-
strate (6). Alternatively, homocysteine is degraded to cysteine via
the transsulfuration pathway in 2 sequential vitamin B-6–depend-
ent reactions (6). Inhibition of homocysteine metabolism as a
result of enzymatic defects or vitamin deficiencies causes homo-
cysteine export into extracellular compartments and thereby
causes elevated plasma tHcy (7).
Despite the strong evidence that tHcy is an independent risk
factor for cardiovascular disease (5), the question of causality
and the mechanism or mechanisms by which tHcy exerts its
pathogenicity are still not clear. Experimental evidence suggests
that the mechanism may be related to the reactivity or redox
properties of the sulfhydryl group (8, 9). If this is the case, other
thiols might also be expected to confer increased cardiovascular
disease risk. Total cysteine (tCys), like homocysteine, is an
aminothiol, and its concentration in plasma is <20-fold
higher than tHcy (<250 mmol/L) (10). However, there are only
2 reports showing higher tCys concentrations in vascular
patients than in healthy control subjects (11, 12). In vascular
disease (11) and in conditions characterized by transient (13,
14) or long-term (15, 16) elevation of tHcy, hyperhomocys-
teinemia was associated with complex changes in tCys and
overall aminothiol redox status. Thus, hyperhomocysteinemia
should not be considered an isolated event, but rather as a com-
ponent of an interactive redox thiol system (10), the impairment
of which may cause vascular lesions.
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In this study we investigated the possible relations between
tCys and several demographic and lifestyle factors associated
with increased cardiovascular disease risk. We used baseline tCys
data from the Hordaland Homocysteine Study of 16176 healthy
women and men (17). In this population, we showed that tHcy
increases with age, is higher in men than in women, and is asso-
ciated with risk factors such as smoking, high blood pressure,
high blood cholesterol concentrations, and low physical activity.
In addition, plasma tHcy is increased by high coffee consumption
and is reduced by intake of folate and vitamins (18). A similar
investigation of tCys may shed light on the possible role of tCys
and tHcy as mediators of cardiovascular disease risk.
SUBJECTS AND METHODS
Study population
From April 1992 to April 1993, the National Health Screening
Services, in cooperation with the University of Bergen and local
health services, conducted the Hordaland Homocysteine Study in
the Hordaland county of western Norway. A total of 24815 women
and men from 3 age groups were invited to participate in the study.
The youngest age group contained all subjects in the county who
were 40–42 y of age. The oldest age group contained all subjects in
Bergen and 3 neighboring suburban municipalities aged 65–67 y.
The middle group, aged 43–64 y, was a 2% random sample of the
residents in the city of Bergen. The attendance rate for the whole
group was 72.7%, constituting a total of 18043 subjects.
To allow for any effect on tCys of disease, treatment, or change
in lifestyle, 1866 participants who reported a previous diagnosis
of coronary heart disease, cerebrovascular disease, hypertension,
or diabetes mellitus were excluded from the analyses. One patient
with homocystinuria was also excluded. Thus, 16176 subjects
were included in this study. Because 96.2% of the participants
belonged to the youngest and oldest age groups, most of the
analyses were confined to these 2 groups. The study protocol was
approved by the Regional Ethical Committee of western Norway,
whose directives are based on the Helsinki Declaration. 
Data collection
Data were collected via questionnaires, examinations, and
blood tests. The questionnaires provided information about age;
smoking habits; physical activity; type of work; personal history
of cardiovascular diseases, hypertension, and diabetes; family
history of disease; recent food intake; lifestyle; medical history;
dietary habits; use of alcohol; and frequency of intake of various
food items and vitamin supplements. Details on the collection
and categorization of data were published previously (17).
Physical activity was categorized as 1) sedentary or no activ-
ity, 2) moderate activity (walking, cycling, or other type of
moderate activity for ‡ 4 h/wk), 3) active exercise (exercise, gar-
dening with physical exertion, or a similar degree of activity for
‡ 4 h/wk, or 4) heavy training (regular heavy training or partici-
pation in competitive sports several times a week). Subjects were
classified into 5 categories: never smokers, former smokers, light
smokers (1–9 cigarettes/d), moderate smokers (10–19 ciga-
rettes/d), and heavy smokers ( ‡ 20 cigarettes/d). Coffee consump-
tion was divided into 5 categories according to the number of
cups consumed per day: 0, <1, 1–4, 5–8, and ‡ 9.
A vitamin-supplement score was created on the basis of use
during the year and frequency of intake during the week of any
type of vitamin supplement and was divided into 5 categories.
The lowest category consisted of subjects who never used vita-
min supplements and the highest category consisted of those
who took vitamins 6–7 d/wk during the whole year (18). A folate
score was computed from food-frequency information and data
on the use of vitamin supplements. The calculation of the folate
score and its validation against plasma folate and tHcy concen-
trations in 329 healthy subjects were reported previously (18).
Clinical examinations, blood sample collection, and
biochemical analysis
The examinations included measurements of height, weight,
and blood pressure; details of the procedures were reported pre-
viously (17). Blood was drawn from nonfasting subjects. Proce-
dures for blood sample collection, processing, transport, and
storage were described previously (17). Plasma tCys and tHcy
were determined by HPLC and fluorescence detection (19, 20).
The precision (between-day CV) of the assay is < 3%. Serum
total cholesterol and triacylglycerol concentrations were meas-
ured with enzymatic methods at the Department of Clinical
Chemistry, Ullevål Hospital, Oslo.
Statistical methods
Because the distribution of tCys was symmetrical, no transfor-
mations were performed; arithmetic means are given for tCys. The
distribution of tHcy was skewed with a long tail toward high values,
and therefore the analyses were done by using log10 tHcy values.
Multiple linear regression models were used to assess the
simultaneous relation among the various predictors of tCys.
Plasma tCys was the dependent variable, whereas the indepen-
dent variables were represented in the models as indicator vari-
ables denoting membership to 1 of 4 categories for cholesterol,
heart rate, diastolic blood pressure, body mass index (BMI),
physical activity, triacylglycerols, and folate intake and member-
ship to 1 of 5 categories for smoking status, coffee consumption,
and vitamin intake. Thus, the regression coefficient was used to
estimate the difference in mean tCys between the reference cat-
egory and the other categories for each factor. tCys concentra-
tions across categories of each risk factor were tested jointly for
homogeneity of means and for linear trend.
The multiple regression technique determines the relation
between a set of independent variables and the mean of a nor-
mally distributed dependent variable (tCys). Thus, this model
implies that the independent variables have the same effect on
high and low values of the dependent variable. Biologically,
however, it is possible that a factor influences extreme high or
low values of the dependent variable with only moderate effects
on the overall mean (21). Such effects can be overlooked with
linear regression but may be studied with a set of logistic regres-
sion analyses, each at a different cutoff for the dichotomous
dependent variable. Therefore, a series of logistic regressions
were performed to assess the effect of the different factors on
high and low tCys concentrations. The 5th (tCys £ 217 mmol/L)
and 95th (tCys ‡ 330 mmol/L) percentiles of the total study sam-
ple were chosen as cutoffs. The results, presented as odds ratios,
represented an estimate of the risk that an individual with a spe-
cific risk profile was hypo- or hypercysteinemic relative to sub-
jects with a baseline risk profile.
Furthermore, Pearson correlation coefficients were computed
to provide a simpler summary of the linear relations between
tCys and the various factors. The analyses were performed by
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using the statistical package BMDP (22). In addition, S-PLUS
software (23) was used to construct Lowess’ plots (24) of the
smoothed relations between 2 variables and to estimate the den-
sity distribution of tCys. All tests were two-tailed, and a P value
< 0.05 was considered significant.
RESULTS
Plasma tCys by age and sex
The distribution of tCys was symmetric. The concentrations
ranged from 72.2 to 441.3 mmol/L, with overall mean and
median values of 270.2 and 268.0 mmol/L, respectively. The dis-
tribution of tCys in the 4 main age and sex groups is shown in
Figure 1. Mean tCys values and the 2.5 and 97.5 percentiles in
the 3 age groups and in both men and women are shown in Table 1.
Mean tCys values were higher in the older groups than in the
youngest group. In the oldest age group there was no sex differ-
ence, whereas in the younger age groups tCys concentrations
were higher in men than in women.
Relation of plasma tCys to cardiovascular disease risk and
lifestyle factors
Predictors of tCys identified in a multiple regression analysis
are shown in Table 2. For all variables, we estimated the differ-
ence in mean tCys concentrations between categories of each risk
factor and its reference category. The results, adjusted for sex,
age, or both, showed that the largest overall differences in tCys
concentrations were observed across different categories of age,
sex, BMI, and cholesterol concentration and, to a lesser extent,
coffee consumption and diastolic blood pressure. Small but signi-
ficant differences in tCys concentrations were found across
different categories of smoking status, but there was no marked
linear trend. Nonsignificant differences in tCys were observed for
physical activity, heart rate, triacylglycerol concentration, and
folate intake (data not shown). Additional adjustment for all fac-
tors in Table 2, in addition to folate score, heart rate, and physi-
cal activity, showed that the relations with age, BMI, cholesterol
concentration, sex, coffee consumption, and diastolic blood pres-
sure remained strong, whereas smoking status no longer con-
tributed to the prediction of tCys concentrations.
To investigate whether the relations between tCys and the
independent variables differed along the tCys distribution, we
performed a series of logistic regressions with high and low
plasma tCys as the outcome variables (Table 3). Age, sex, BMI,
cholesterol concentration, diastolic blood pressure, and coffee
consumption were associated with a shift of the tCys distribution
to higher values. Although the associations with age and sex
were somewhat stronger at low concentrations and stronger with
BMI at high concentrations, the analyses of tail effects provided
essentially the same information as the analyses of mean plasma
tCys concentrations.
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FIGURE 1. Distribution of plasma total cysteine (tCys) in the 4 main age and sex groups.
TABLE 1
Plasma total cysteine (tCys) concentration by age and sex
40–42 y 43–64 y 65–67 y
Sex n tCys n tCys n tCys P1
mmol/L mmol/L mmol/L
Male 5918 273.1 (218.6–338.4)2 287 279.5 (225.6–332.8) 1386 296.4 (232.9–362.2) < 0.001
Female 6348 253.1 (202.1–317.1) 305 275.8 (215.4–347.2) 1932 296.3 (233.5–360.5) < 0.001
1 For linear trend.
2 x– (2.5–97.5 percentiles).







We also studied possible effect modifications by age and sex by
investigating the correlations between tCys and the various factors
in subgroups (Table 4). In all age and sex groups, plasma tCys con-
centrations correlated strongly with BMI (Figure 2) and also cor-
related with cholesterol concentration and diastolic blood pressure.
The relation with BMI was attributed mainly to weight and not to
height (data not shown). The association of tCys with coffee intake
was strongest in the youngest age group. In contrast, smoking was
negatively associated with tCys in the elderly. Weaker or no corre-
lations were found between tCys and triacylglycerols, heart rate,
physical activity, and vitamin intake (data not shown).
There was a strong nonlinear relation between tCys and tHcy.
Up to a tHcy concentration of 12 mmol/L, there was a strong
positive association between tCys and tHcy, but at higher tHcy
concentrations the relation was inverse (Figure 3). To exclude
the possibility that the associations between tCys and the vari-
ous factors investigated were secondary to changes in tHcy, we
repeated the correlation analyses after dividing the subjects into
those with tHcy concentrations > 12 mmol/L and those with
tHcy concentrations £ 12 mmol/L. The association between tCys
and the various factors (except for tHcy) remained essentially
unaltered (Table 4).
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TABLE 2
Estimated change in plasma total cysteine (tCys) concentration by cardiovascular disease risk factor1
Estimated change in tCys Estimated change in tCys
Risk factor Adjusted for sex, age, or both P Multiple adjustment2 P
mmol/L mmol/L
Sex
Female (n = 8585)3
Male (n = 7591) 15.35 (14.39, 16.31) <0.0014,5 14.71 (13.28, 16.14) <0.0014,5
Age (y)
40–42 (n = 12266)3
43–64 (n = 592) 14.81 (12.26, 17.37) <0.0014,5 9.64 (6.42, 12.87) <0.0014,5
65–67 (n = 3318) 34.59 (33.40, 35.78) 29.56 (27.72, 31.40)
BMI (kg/m2)
< 20 (n = 873)3
20–24.99 (n = 8358) 7.21 (5.10, 9.33) 6.01 (3.31, 8.72)
25–29.99 (n = 5731) 17.29 (15.11, 19.48) <0.0014,5 14.09 (11.25, 16.94) <0.0014,5
‡ 30 (n = 1191) 29.00 (26.35, 31.65) 26.54 (23.01, 30.08)
Cholesterol (mmol/L)
< 4.00 (n = 570)3
4.00–5.99 (n = 9235) 9.58 (6.98, 12.18) 7.82 (4.65, 10.98)
6.00–7.99 (n = 5627) 16.48 (13.80, 19.16) <0.0014,5 12.92 (9.58, 16.26) <0.0014,5
‡ 8.00 (n = 746) 21.99 (18.55, 25.42) 18.44 (13.84, 23.05)
Diastolic blood pressure (mm Hg)
< 70 (n = 2583)3
70–84 (n = 8571) 4.80 (3.43, 6.16) 2.92 (1.23, 4.60)
85–99 (n = 4149) 9.75 (8.20, 11.30) <0.0014,5 5.83 (4.10, 7.57) <0.0014,5
‡ 100 (n = 847) 13.69 (11.24, 16.14) 8.27 (4.88, 11.67)
Coffee (cups/d)
0 (n = 1285)3
< 1 (n = 485) 6.29 (3.08, 9.51) 6.02 (2.09, 9.96)
1–4 (n = 8146) 11.15 (9.33, 12.97) <0.0014,5 10.46 (8.21, 12.70) <0.0014,5
5–8 (n = 5286) 13.56 (11.68, 15.44) 14.42 (12.06, 16.79)
‡ 9 (n = 974) 16.19 (13.61, 18.76) 14.90 (11.54, 18.26)
Smoking status
Never smoker (n = 6078)3
Former smoker (n = 4140) 0.81 (20.42, 2.05) 21.12 (22.65, 0.40)
Light smoker (n = 1373) 21.75 (23.56, 0.07) 0.0024 21.71 (24.06, 0.64) 0.044
Moderate smoker (n = 3228) 21.66 (22.99, 20.32) 0.135 22.72 (24.47, 20.97) 0.005
Heavy smoker (n = 1278) 1.15 (20.75, 3.04) 21.25 (23.82, 1.32)
Vitamin supplement score6
Level 0 (n = 4066)3
Level 1 (n = 1904) 0.05 (21.65, 1.74) 20.70 (22.54, 1.15)
Level 2 (n = 2675) 0.23 (21.31, 1.77) 0.994 21.22 (23.39, 0.96) 0.604
Level 3 (n = 1685) 0.07 (21.72, 1.87) 0.765 21.36 (24.37, 1.65) 0.075
Level 4 (n = 1612) 0.39 (21.44, 2.22) 0.12 (23.33, 3.56)
1 95% CIs in parentheses.
2 Adjusted for all risk factors in this table and for folate score, physical activity, and heart rate.
3 Reference category.
4 All levels of the risk factor were tested jointly (test for homogeneity).
5 For linear trend.
6 Level 0 included subjects who had never used vitamin supplements and level 4 included subjects who used supplements 6–7 d/wk during the whole year.







Lifestyle and risk factors according to tCys and tHcy response
To summarize the results and to highlight the differences
between tCys and tHcy as response indicators, we grouped the
lifestyle and risk factors into 4 categories according to the com-
bined relations with tCys and tHcy (Figure 4). Group 1 were fac-
tors associated with both tCys and tHcy: age, cholesterol con-
centration, diastolic blood pressure, and coffee consumption.
BMI was strongly related to tCys but not to tHcy (group 2),
whereas smoking status, folate and vitamin intakes, heart rate,
and physical activity were mainly associated with tHcy and not
with tCys (group 3). Finally, triacylglycerol concentrations were
weakly associated with both aminothiols (group 4).
DISCUSSION
We investigated plasma tCys concentrations and their relation
to lifestyle and cardiovascular disease risk factors among 16 176
healthy adults in the Hordaland Homocysteine Study. The
strongest determinants of tCys were age, BMI, sex, diastolic
blood pressure, serum cholesterol concentration, and coffee con-
sumption. These factors, except for BMI, were also associated
with tHcy, which in turn showed relations not shown for tCys
(17, 25). On the basis of their relation with tCys and tHcy con-
centrations, these factors were divided into 4 groups, as depicted
in Figure 4. Such classification may point to possible mecha-
nisms behind the associations and to a possible role of tCys as a
cardiovascular disease risk factor.
Age, sex, cholesterol concentration, diastolic blood pressure,
and coffee consumption were strong determinants of both tHcy
and tCys and therefore complied with the criteria of group 1. Like
tHcy (17, 26), tCys (Table 1) increased with age in both men and
women. As with tHcy (27), the effect was most pronounced at the
lower part of the tCys distribution (Table 3). Possible mechanisms
are an age-dependent decrease in enzymatic activities involved in
both cysteine and homocysteine metabolism (28) and impaired
renal function. The latter possibility is supported by consistent
observations that tCys and tHcy increase considerably in renal
insufficiency (29). Notably, the decline in glomerular filtration rate
may explain the age-related increase in tCys and tHcy (30).
Some (31), but not all (32), previous studies showed higher
tCys concentrations in men than in women; such sex differ-
ences have been consistently shown for tHcy (17, 26). In the
present study, plasma tCys concentrations were higher in men
than in women in the youngest but not in the older age groups.
The sex difference may have been due to hormonal effects,
which vanish at advanced ages. Higher creatine-creatinine syn-
thesis (a function of muscle mass and the major source of Hcy
formation) in men than in women may contribute to the sex dif-
ference in tHcy concentration (26) but may have less of an
effect on cysteine homeostasis.
Both tCys and tHcy were related to cholesterol concentration
and diastolic blood pressure, and the relations remained strong
after adjustment for other risk factors (Table 2). We are aware of no
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TABLE 3
Odds ratio (OR) for hypo- and hypercysteinemia, adjusted for sex and age, by cardiovascular disease risk factor1
tCys £ 217 mmol/L tCys ‡ 330 mmol/L
Risk factor OR (95% CI) 1/OR P2 OR (95% CI) P2
Sex
Female (n = 8585)3 1 1
Male (n = 7591) 0.21 (0.17, 0.26) 4.68 < 0.001 1.61 (1.41, 1.88) < 0.001
Age (y)
40–42 (n = 12266)3 1 1
43–64 (n = 592) 0.29 (0.16, 0.54) 3.42 < 0.001 2.11 (1.46, 3.07) < 0.001
65–67 (n = 3318) 0.09 (0.06, 0.14) 11.1 6.68 (5.76, 7.74)
BMI (kg/m2)
<20 (n = 873)3 1 1
20–24.99 (n = 8358) 0.70 (0.55, 0.89) 1.43 1.95 (1.11, 3.44)
25–29.99 (n = 5731) 0.41 (0.31, 0.54) 2.44 < 0.001 3.84 (2.18, 6.75) < 0.001
‡ 30 (n = 1191) 0.26 (0.17, 0.42) 3.82 9.03 (5.06, 16.1)
Cholesterol (mmol/L)
4.00 (n = 570)3 1 1
4.00–5.99 (n = 9235) 0.57 (0.43, 0.76) 1.75 1.39 (0.75, 2.57)
6.00–7.99 (n = 5627) 0.39 (0.28, 0.53) 2.60 < 0.001 2.05 (1.11, 3.79) < 0.001
‡ 8.00 (n = 746) 0.42 (0.22, 0.79) 2.38 3.25 (1.71, 6.18)
Diastolic blood pressure (mm Hg)
<70 (n = 2583)3 1 1
70–84 (n = 8571) 0.80 (0.67, 0.96) 1.24 1.48 (1.12, 1.95)
85–99 (n = 4149) 0.60 (0.48, 0.77) 1.66 < 0.001 2.19 (1.65, 2.90) < 0.001
‡ 100 (n = 847) 0.48 (0.28, 0.85) 2.07 2.75 (1.97, 3.83)
Coffee, (cups/d)
0 (n = 1285)3 1 1
<1 (n = 485) 0.71 (0.45, 1.10) 1.42 1.70 (0.98, 2.97)
1–4 (n = 8146) 0.59 (0.47, 0.73) 1.70 1.87 (1.27, 2.75)
5–8 (n = 5286) 0.42 (0.33, 0.53) 2.40 < 0.001 2.10 (1.41, 3.12) < 0.001
‡ 9 (n = 974) 0.42 (0.28, 0.64) 2.36 2.70 (1.69, 4.32)
1 tCys, plasma total cysteine concentration.
2 For linear trend.
3 Reference category.







experimental or clinical observations that explain the relation
between plasma aminothiol and cholesterol concentrations. The
association of both tCys and tHcy with blood pressure may be
related to the fact that both compounds react with nitric oxide to
form vasoactive nitrosothiol adducts (8). In addition, cysteine may
exert endothelium-dependent contraction by generating O2–, which
rapidly inactivates the endothelium-derived relaxing factor (33).
A moderately strong relation between tCys and coffee con-
sumption was observed. A similar relation was seen with tHcy
and was attributed to the possible influence of caffeine (27).
Notably, coffee consumption was associated with a complete
shift of the tCys distribution (Table 3), but it was related to tHcy
only at low concentrations (27).
BMI was a strong determinant of tCys in both men and
women and in both age groups and was particularly predictive of
high tCys concentrations. BMI has only rarely been associated
with tHcy concentrations (34); in the present study we found no
association and, therefore, BMI was classified as a group 2 fac-
tor. The mechanism for the association between BMI and tCys is
unclear, but the association may reflect a possible role of plasma
cysteine availability in stabilizing body cell mass (35).
Smoking status, vitamin and folate intakes, physical activity,
and heart rate are determinants of plasma tHcy concentrations (17)
but were essentially unrelated to tCys (Figure 4). Accordingly,
these factors were classified as group 3 factors. However, the dif-
ferential effects were not absolute because tCys was weakly
related to heart rate and weakly and inversely related to smoking
in elderly men and women. In young men and women, tCys was
unrelated to smoking. In line with these findings, a recent study
showed no effect of smoking on various cysteine forms in plasma
(32). On the contrary, plasma tHcy showed a significant relation
with smoking status that may have been attributable to changes in
the thiol redox status or to the lower concentrations of plasma
folate and vitamin B-12 in smokers (36).
As expected, tCys was unrelated to the intake of vitamin sup-
plements or to the folate score, both of which are strong deter-
minants of tHcy (Figure 4) (17, 18). Vitamin B-6, which is a
cofactor in the 2 sequential enzymes that convert homocysteine
into cysteine (6), was not assessed in the present study but
should be considered as a possible factor for explaining some of
the relations between tCys and several lifestyle factors. For
instance, the strong relation between tHcy and coffee consump-
tion (27) may have been due to impaired vitamin B-6 function,
especially if caffeine functions as a vitamin B-6 antagonist, as
shown recently for another xanthine derivative, theophylline
(37). However, inhibition of the transsulfuration pathway is
expected to decrease tCys, whereas we found that tCys increased
in coffee drinkers. Smoking may also impair vitamin B-6 status,
but elevated tHcy (38) and low tCys (Table 4) concentrations
were observed only in the elderly smokers. Thus, our data do not
support the hypothesis that coffee and smoking affect tCys by
interfering with vitamin B-6 status. However, caffeine was
shown recently to reduce the glomerular filtration rate (39), an
effect that may partly have accounted for the increase in concen-
trations of both tCys and tHcy.
The present study has no clinical endpoints but addresses
several questions of clinical relevance. Despite the relation
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FIGURE 2. Relation between plasma total cysteine (tCys) and BMI
in the 4 main age and sex groups.
TABLE 4
Correlation coefficients for plasma total cysteine concentrations with cardiovascular disease risk factors in young and old women and men and in subjects
with a plasma total homocysteine (tHcy) concentration £ 12 mmol/L (low) or > 12 mmol/L (high)1
40–42 y 65–67 y
Men Women Men Women
All Low High All Low High All Low High All Low High
Risk factor (n = 5918) (n = 4212) (n = 1706) (n = 6348) (n = 5434) (n = 914) (n = 1386) (n = 702) (n = 684) (n = 1932) (n = 1282) (n = 650)
BMI 0.25 0.25 0.25 0.22 0.22 0.24 0.21 0.21 0.24 0.30 0.31 0.31
Cholesterol concentration 0.14 0.14 0.10 0.12 0.12 0.09 0.10 0.032 0.15 0.05 0.052 0.032
Diastolic blood pressure 0.15 0.13 0.14 0.12 0.12 0.10 0.14 0.10 0.15 0.08 0.10 0.042
Coffee consumption 0.11 0.09 0.06 0.15 0.13 0.12 0.07 0.072 20.012 0.06 0.032 0.052
Smoking status 20.022 20.05 20.06 0.03 0.022 20.052 20.06 20.08 20.12 20.07 20.13 20.11
tHcy 0.27 0.35 20.13 0.33 0.40 20.23 0.26 0.36 20.042 0.30 0.33 20.062
1 All coefficients significant (P < 0.05) unless marked otherwise.
2 NS.







between tCys and tHcy (Figure 3), the unique associations
observed for each aminothiol (Figure 4) suggest that tCys and
tHcy may confer independent cardiovascular disease risk. The
possibility of an effect of tCys independent of tHcy is supported
by similar relations between tCys and BMI, coffee consump-
tion, serum cholesterol concentration, and blood pressure in
subgroups with a high or low tHcy concentration (Table 4). Sev-
eral in vitro studies on vascular or atherogenic effects of ami-
nothiols showed similar effects for cysteine and homocysteine
(5, 40). Such findings have been interpreted as a lack of speci-
ficity for homocysteine (5, 40) but could suggest that high con-
centrations of tCys and tHcy have a synergistic effect. Such syn-
ergy may explain the high cardiovascular mortality and
morbidity predicted by hyperhomocysteinemia in patients with
renal failure (41, 42), which, in contrast with vitamin defi-
ciency, elevates both tHcy and tCys concentrations (43).
In conclusion, both tHcy and tCys are interactive components
that undergo disulfide exchange and redox reactions (plasma
redox thiol status) (10). Although tHcy has been established as
an independent cardiovascular disease risk factor (5), only sparse
data link tCys to human health and disease. Our study showed
that tCys is strongly related to several biochemical, physical, and
lifestyle factors, some of which also correlate with tHcy. Thus,
these plasma aminothiols have distinct correlation profiles with
established cardiovascular disease risk factors. Our data may
suggest interactive effects in relation to the pathogenesis of vas-
cular disease and should motivate clinical studies of these ami-
nothiols as risk factors.
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FIGURE 3. Relation between plasma total cysteine (tCys) and plasma total homocysteine (tHcy) in the 4 main age and sex groups.
FIGURE 4. Relation between plasma total cysteine (tCys) and plasma total homocysteine (tHcy) and various cardiovascular disease risk factors.
The minus sign indicates a negative correlation. P > 0.05.
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